In May 2026, ScienceDaily covered the results of the University of Kansas Medical Center's CABA trial (Creatine to Augment Bioenergetics in Alzheimer's). The study enrolled 240 participants with early-stage Alzheimer's disease. Half received 5 grams of oral creatine daily for 12 weeks. Half received placebo.
The results were striking. Participants taking creatine showed a 10-15% increase in brain phosphocreatine levels on MRS (magnetic resonance spectroscopy) scans. More importantly, the intervention group showed approximately 30% slower decline on standard cognitive assessment scales compared to placebo.
This wasn't a marginal finding. A 30% reduction in the rate of cognitive decline, from a supplement that costs less than a dollar a day, in a disease with limited treatment options — that's a result that reframes how we think about creatine entirely.
Why It Works: The ATP Connection
Your brain is roughly 2% of your body weight but consumes about 20% of your total energy. That energy comes from ATP (adenosine triphosphate), the same molecule your muscles use during a deadlift. When ATP is spent, it becomes ADP. Phosphocreatine donates a phosphate group to recycle ADP back into ATP.
This is why creatine works for both bench pressing and board meetings. The energy currency is identical. When you're deep in a complex problem — debugging a race condition, evaluating a product roadmap, writing a technical spec — your prefrontal cortex is burning through ATP at a rate that can outpace your body's ability to regenerate it. Creatine tops off the reserve.
The CABA trial demonstrated this directly: supplementation increased measurable phosphocreatine in brain tissue. More fuel in the tank means more sustained cognitive output before the system degrades.